JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Heron Therapeutics Inc

Закрыт

СекторЗдравоохранение

1.2 1.69

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.18

Макс.

1.2

Ключевые показатели

By Trading Economics

Доход

-5M

-2.4M

Продажи

-1.7M

37M

Рентабельность продаж

-6.401

Сотрудники

122

EBITDA

-5.3M

-1.6M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+275% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-20M

247M

Предыдущая цена открытия

-0.49

Предыдущая цена закрытия

1.2

Новостные настроения

By Acuity

50%

50%

147 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

Heron Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 18:41 UTC

Отчет

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 окт. 2025 г., 18:31 UTC

Отчет

Correction to Procter & Gamble to Focus on Innovation

24 окт. 2025 г., 16:25 UTC

Главные движущие силы рынка

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 окт. 2025 г., 19:29 UTC

Обсуждения рынка

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 окт. 2025 г., 18:52 UTC

Отчет

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:41 UTC

Отчет

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:03 UTC

Отчет

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 окт. 2025 г., 18:02 UTC

Отчет

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 окт. 2025 г., 18:00 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 окт. 2025 г., 16:57 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 окт. 2025 г., 16:54 UTC

Обсуждения рынка

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 окт. 2025 г., 16:44 UTC

Обсуждения рынка
Отчет

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 окт. 2025 г., 16:39 UTC

Обсуждения рынка
Отчет

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 окт. 2025 г., 16:33 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:23 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 16:07 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Heron Therapeutics Inc Прогноз

Целевая цена

By TipRanks

275% рост

Прогноз на 12 месяцев

Средняя 4.5 USD  275%

Максимум 6 USD

Минимум 3 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Heron Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

2

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

2.0001 / 2.42Поддержка и Сопротивление

Краткосрочная

Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

147 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat